{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:39:50Z","timestamp":1782823190925,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T19:38:40Z","timestamp":1681933120000},"page":"3347-3357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A thermostable, dry formulation inactivated Hikojima whole cell\/cholera toxin B subunit oral cholera vaccine"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-3210","authenticated-orcid":false,"given":"Manuela","family":"Terrinoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4238-6004","authenticated-orcid":false,"given":"Stefan L.","family":"Nordqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"L\u00f6fstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"K\u00e4llg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Lebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Holmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10101","key":"10.1016\/j.vaccine.2023.04.004_b0005","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0140-6736(17)30559-7","article-title":"Cholera","volume":"390","author":"Clemens","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2023.04.004_b0010","doi-asserted-by":"crossref","first-page":"e0003832","DOI":"10.1371\/journal.pntd.0003832","article-title":"Updated global burden of cholera in endemic countries","volume":"9","author":"Ali","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.04.004_b0015","unstructured":"WHO, World Health Organization. Cholera vaccines: WHO position paper. Weekly Epidemiol. Rec. 2017; 92 (34): 477\u2013500."},{"key":"10.1016\/j.vaccine.2023.04.004_b0020","unstructured":"WHO, World Health Organization. Cholera: mechanism for control and prevention (World Health Assembly 64 session, agenda item 13.9). Geneva; 2011."},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.004_b0025","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrgastro.2011.174","article-title":"New-generation vaccines against cholera","volume":"8","author":"Clemens","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.004_b0030","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/S2214-109X(16)00037-1","article-title":"A second affordable oral cholera vaccine: implications for the global vaccine stockpile","volume":"4","author":"Desai","year":"2016","journal-title":"Lancet Glob Health"},{"issue":"13","key":"10.1016\/j.vaccine.2023.04.004_b0035","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0264-410X(92)90324-D","article-title":"An oral B subunit: whole cell vaccine against cholera","volume":"10","author":"Holmgren","year":"1992","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2023.04.004_b0040","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2018.09.026","article-title":"The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships","volume":"36","author":"Odevall","year":"2018","journal-title":"Vaccine"},{"issue":"9702","key":"10.1016\/j.vaccine.2023.04.004_b0045","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0140-6736(09)61297-6","article-title":"Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial","volume":"374","author":"Sur","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.004_b0050","unstructured":"WHO. Global Taskforce on Cholera Control. Ending Cholera _ A Global Roadmap to 2030. https:\/\/www.who.int\/cholera\/publications\/global-roadmap\/en\/; 2017,Oct 3."},{"key":"10.1016\/j.vaccine.2023.04.004_b0055","unstructured":"GAVI. Cholera Supply and Procurement Roadmap Update, Available online: https:\/\/www.gavi.org\/sites\/default\/files\/document\/cholera-roadmap-public-summarypdf.pdf (accessed on 10 March 2021). December 2018."},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.004_b0060","article-title":"Oral Cholera Vaccine Efficacy and Effectiveness","volume":"9","author":"Song","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.vaccine.2023.04.004_b0065","doi-asserted-by":"crossref","first-page":"e108521","DOI":"10.1371\/journal.pone.0108521","article-title":"Development of stable Vibrio cholerae O1 Hikojima type vaccine strains co-expressing the Inaba and Ogawa lipopolysaccharide antigens","volume":"9","author":"Karlsson","year":"2014","journal-title":"PLoS One"},{"issue":"50","key":"10.1016\/j.vaccine.2023.04.004_b0070","doi-asserted-by":"crossref","first-page":"7998","DOI":"10.1016\/j.vaccine.2020.10.043","article-title":"Development of Hillchol\u00ae, a low-cost inactivated single strain Hikojima oral cholera vaccine","volume":"38","author":"Sharma","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.004_b0075","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejpb.2011.06.009","article-title":"Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation","volume":"79","author":"Borde","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2023.04.004_b0080","article-title":"A novel non-antibiotic, lgt-based selection system for stable maintenance of expression vectors in Escherichia coli and Vibrio cholerae","author":"Terrinoni","year":"2017","journal-title":"Appl Environ Microbiol"},{"issue":"13","key":"10.1016\/j.vaccine.2023.04.004_b0085","first-page":"1574","article-title":"Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines","volume":"11","author":"Lebens","year":"1993","journal-title":"Biotechnology (N Y)"},{"key":"10.1016\/j.vaccine.2023.04.004_b0090","doi-asserted-by":"crossref","unstructured":"Osek et al. Improved medium for large-scale production of recombinant cholera toxin B subunit for vaccine purposes. J Microbiol Methods December 1995; 24(2): 117\u2013123.","DOI":"10.1016\/0167-7012(95)00061-5"},{"key":"10.1016\/j.vaccine.2023.04.004_b0095","unstructured":"Sharma et al. A novel process for production of purified recombinant cholera toxin b (rCTB) and formulation thereon. International patent application WO2017103748A1 (Applicant MSD Wellcome Trust Hilleman Laboratories). https:\/\/patents.google.com\/patent\/WO2017103748A1. 2016."},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.004_b0100","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/jcm.17.4.596-600.1983","article-title":"Rapid GM1-enzyme-linked immunosorbent assay with visual reading for identification of Escherichia coli heat-labile enterotoxin","volume":"17","author":"Svennerholm","year":"1983","journal-title":"J Clin Microbiol"},{"issue":"43","key":"10.1016\/j.vaccine.2023.04.004_b0105","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1016\/j.vaccine.2011.06.121","article-title":"Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens","volume":"29","author":"Lebens","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.004_b0110","article-title":"An Update on Cholera Immunity and Current and Future Cholera Vaccines","volume":"6","author":"Holmgren","year":"2021","journal-title":"Trop Med Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2023.04.004_b0115","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/S1473-3099(22)00215-8","article-title":"Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges","volume":"22","author":"Deen","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.004_b0120","unstructured":"ICG. International Coordinating Group . Shortage of cholera vaccines leads to temporary suspension of two-dose strategy, as cases rise worldwide. https:\/\/www.ifrc.org\/press-release\/shortage-cholera-vaccines-leads-temporary-suspension-two-dose-strategy-cases-rise. Press release 19 Oct 2022. ."},{"key":"10.1016\/j.vaccine.2023.04.004_b0125","unstructured":"WHO. World Health Organization. Assessing the programmatic suitability of vaccines candidates for WHO prequalification, Revision 2014. https:\/\/www.who.int\/publications\/i\/item\/WHO-IVB-14.10; 2015."},{"issue":"6","key":"10.1016\/j.vaccine.2023.04.004_b0130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14760584.2022.2053678","article-title":"Thermostable vaccines: an innovative concept in vaccine development","volume":"21","author":"Kumar","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.004_b0135","unstructured":"CEPI. Coalition for Epidemic Preparedness Innovations . Call for Proposals: Innovative technologies to improve vaccine thermostability. https:\/\/cepi.net\/news_cepi\/cepi-opens-call-to-develop-heat-stable-vaccine-tech-for-use-against-epidemic-and-pandemic-threats\/; 2022."},{"key":"10.1016\/j.vaccine.2023.04.004_b0140","unstructured":"Kahn A-L. An update on who work in support of the controlled temperature chain (CTC) https:\/\/www.unicef.org\/supply\/media\/3216\/file\/VIC-2019-Session-6-Pres-3-CTCupdate.pdf; 2019."},{"issue":"32","key":"10.1016\/j.vaccine.2023.04.004_b0145","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1016\/j.vaccine.2021.06.069","article-title":"A phase I\/II study to evaluate safety, tolerability and immunogenicity of Hillchol(R), an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh","volume":"39","author":"Chowdhury","year":"2021","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2023.04.004_b0150","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1016\/j.vaccine.2017.03.081","article-title":"Economic impact of thermostable vaccines","volume":"35","author":"Lee","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:23:16Z","timestamp":1715127796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23003870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":30,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23003870"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A thermostable, dry formulation inactivated Hikojima whole cell\/cholera toxin B subunit oral cholera vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}